Acadia Pharmaceuticals ACAD Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's accounts receivable?
- Acadia Pharmaceuticals (ACAD) reported accounts receivable of $135.35M in Q1 2026.
- How has Acadia Pharmaceuticals's accounts receivable changed year-over-year?
- Acadia Pharmaceuticals's accounts receivable increased by 28.0% year-over-year, from $105.74M to $135.35M.
- What is the long-term trend for Acadia Pharmaceuticals's accounts receivable?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's accounts receivable has grown at a 20.3% compound annual growth rate (CAGR), from $48.25M to $121.46M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.